Private Trust Company’s United Therapeutics UTHR Stock Holding History

Private Trust Company’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$39K	Hold	72	–	–	﹤0.01%	1500
2026 Q1	$42.7K	Hold	72	–	–	﹤0.01%	1371
2025 Q4	$35.1K	Sell	72 -5	-6%	-$2.33K	﹤0.01%	1409
2025 Q3	$32.3K	Sell	77 -13	-14%	-$4.37K	﹤0.01%	1439
2025 Q2	$25.9K	Sell	90 -4	-4%	-$1.2K	﹤0.01%	1468
2025 Q1	$29K	Buy	94 +20	+27%	+$6.85K	﹤0.01%	1407
2024 Q4	$26.1K	Buy	74 +6	+9%	+$2.21K	﹤0.01%	1399
2024 Q3	$24.4K	Sell	68 -6	-8%	-$2.03K	﹤0.01%	1397
2024 Q2	$23.6K	Hold	74	–	–	﹤0.01%	1394
2024 Q1	$17K	Buy	74 +2	+3%	+$451	﹤0.01%	1489
2023 Q4	$15.8K	Sell	72 -2	-3%	-$461	﹤0.01%	1489
2023 Q3	$16.7K	Buy	74 +6	+9%	+$1.38K	﹤0.01%	1419
2023 Q2	$15K	Hold	68	–	–	﹤0.01%	1470
2023 Q1	$15.2K	Buy	68 +12	+21%	+$2.96K	﹤0.01%	1435
2022 Q4	$16K	Hold	56	–	–	﹤0.01%	1389
2022 Q3	$12K	Hold	56	–	–	﹤0.01%	1392
2022 Q2	$13K	Buy	+56	New	+$11.4K	﹤0.01%	1397
2014 Q2	–	Sell	-22	Closed	-$2K	–	2005
2014 Q1	$2K	Sell	22 -22	-50%	-$2.25K	﹤0.01%	1510
2013 Q4	$5K	Hold	44	–	–	﹤0.01%	1177
2013 Q3	$3K	Hold	44	–	–	﹤0.01%	1307
2013 Q2	$3K	Buy	+44	New	+$2.83K	﹤0.01%	1246

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Private Trust Company's UTHR Position: Q2 2026 in Review

Private Trust Company held its United Therapeutics (UTHR) position steady in Q2 2026 at 72 shares worth $39K. The position accounts for ﹤0.01% of the portfolio, ranked #1500.

Private Trust Company first reported a position in UTHR in Q2 2013 and has held it in 21 quarters since. The position peaked at $42.7K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Private Trust Company held 72 shares of United Therapeutics worth $39K as of Q2 2026.
Private Trust Company left its United Therapeutics share count unchanged in Q2 2026.
United Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q2 2026, its #1500 holding.
Private Trust Company first reported a position in United Therapeutics in Q2 2013 and has held it in 21 quarters since.
Private Trust Company's United Therapeutics position peaked at $42.7K in Q1 2026.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.